The FINANCIAL -- CAMBRIDGE, Mass. -- Dyax Corp., a developer of novel biotherapeutics for
unmet medical needs, announced today that executive management will
present at two investor conferences in September, providing a corporate
update regarding the Company's three major business franchises and value
drivers - KALBITOR® (ecallantide), the Licensing and Funded Research
Program (LFRP) and the internal pipeline, including label expansion
efforts with KALBITOR.
George Migausky, Executive Vice President and Chief Financial Officer, will present on Tuesday, September 13 at 9:10 AM (ET) at the Rodman & Renshaw Annual Global Investment Conference being held September 11-13 at the Waldorf Astoria, New York City.
Gustav Christensen, President and Chief Executive Officer, will present on Monday, September 19 at 1:00 PM (ET) at the UBS Global Life Sciences Conference being held September 19-21 at the Grand Hyatt Hotel, New York City.
Related Stories
